This content has not been reviewed within the past year and may not represent Web MD's most up-to-date information. To find the most current information, please enter your topic of interest into our search box. " March 1, 2002 -- A popular diabetes drug may hold the key to motherhood for millions of women with the most common form of infertility. Miscarriage rates dropped dramatically among a group of women with polycystic ovary syndrome (PCOS) treated with the drug metformin. Researchers say the drug, also known as Glucophage, is also highly effective in preventing gestational diabetes, a form of diabetes that is common in pregnant women with PCOS, and may be a better treatment than insulin for all women with pregnancy-related diabetes. "This therapy is rapidly revolutionizing the treatment of infertility, and with good reason," says Charles Glueck, MD, who conducted some of the first metformin infertility studies and has treated almost 1,500 women with the syndrome. "In women with PCOS the risk of miscarriage is very high, around 50%. Design Population based exploratory case-control study using malformed controls. Cases of 29 specific subgroups of non-genetic anomalies, and all non-genetic anomalies combined, were compared with controls (all other non-genetic anomalies or genetic syndromes). Participants 50 167 babies affected by congenital anomaly (41 242 non-genetic and 8925 genetic) including live births, fetal deaths from 20 weeks’ gestation, and terminations of pregnancy for fetal anomaly. Results 168 babies affected by congenital anomaly (141 non-genetic and 27 genetic) were exposed to metformin, 3. births. No evidence was found for a higher proportion of exposure to metformin during the first trimester among babies with all non-genetic anomalies combined compared with genetic controls (adjusted odds ratio 0.84, 95% confidence interval 0.55 to 1.30). The only significant result was for pulmonary valve atresia (adjusted odds ratio 3.54, 1.05 to 12.00, compared with non-genetic controls; 2.86, 0.79 to 10.30, compared with genetic controls). Conclusions No evidence was found for an increased risk of all non-genetic congenital anomalies combined following exposure to metformin during the first trimester, and the one significant association was no more than would be expected by chance.
The early literature regarding metformin use in early pregnancy in humans was based on. If you become pregnant while using metformin, you should not stop your. High blood sugar levels before and during pregnancy increase the chance of birth.